MSCI global small-cap index adjustment imminent, DUALITYBIO-B(09606) and others will be included.

08/08/2025

On August 8, MSCI, a globally renowned index company, announced the results of the index quarterly review for August 2025. In this adjustment, many companies including Innovent Biologics-B (09606) will be included in the MSCI Global Small Cap Index, officially entering the "global assets" category.

On August 8th, the globally renowned index company MSCI announced the results of the index quarterly review for August 2025. In this adjustment, several companies including DUALITYBIO-B (09606) will be included in the MSCI Global Small Cap Index, officially joining the ranks of "global assets". This adjustment will take effect after the close of trading on August 26th. The closing auction transaction of the newly added companies will be enlarged on the same day, as passive funds concentrate on buying, with limited short-term stock price impact. However, in the long run, they will continue to benefit from funds, valuation, and brand aspects.

UCD (01599) issues profit warning, expects mid-term net profit to decrease by approximately 31% to 41% year-on-year.

JUNSHI BIO (688180.SH): The new indication for the first-line treatment of HER2-expressing urothelial carcinoma with Trastuzumab has been accepted for market application.

Chairman Lun Yiu Kee reduced his stake in MEXAN (00022) by 1.28 million shares, with each share priced at approximately HK$0.17.

UCD (01599) issues profit warning, expects mid-term net profit to decrease by approximately 31% to 41% year-on-year.

JUNSHI BIO (688180.SH): The new indication for the first-line treatment of HER2-expressing urothelial carcinoma with Trastuzumab has been accepted for market application.

Chairman Lun Yiu Kee reduced his stake in MEXAN (00022) by 1.28 million shares, with each share priced at approximately HK$0.17.